ClinicalTrials.gg
Not yet recruitingNCT07802600Updated Sep 3, 2026

Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children

An observational study in Fungal Infection by Site and Tinea Capitis, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
1 Year to 18 Years
Sex
All
01

Study summary

Tinea capitis is a common dermatophyte infection of the scalp in children aged 0-9 years .The prevalence of tinea capitis in Egypt is 0.4% and higher in public than private schools, Boys were more affected than girls according to children by 5:1 ratio , It is more prevalent in those who live in urban areas, large families, low socioeconomic level, crowded living conditions and immunocompromised people . Tinea capitis is caused by dermatophyte fungi Trichophyton and Microsporum genera. These fungi are classified as: anthropophilic, zoophilic, and geophilic according to the route of infection. These fungi invade the hair shaft in two routes: ectothrix and endothrix . T.tonsurans and T.violaceum are reported to be the most common cause of tinea capitis

Read the detailed description

Clinical types of tinea capitis include : scaly type (characterized by fine scaling and circular alopecia), black dot (characterized by non-inflammatory patches with broken-off, swollen hair stubs), tinea agminate (patchy alopecia with scattered pustules or low-grade folliculitis), kerion (painful, boggy, inflammatory masses with alopecia, often confused with bacterial abscess) and favus (scutula, mousy odor) . Tinea incognito (steroid modified tinea) refers to dermatophytosis that has lost their usual clinical appearance due to the use of steroids.

The main clinical feature of dermatophyte scalp infections is the appearance of scaling of the scalp skin, which is associated with a variable degree of inflammation and itching . In some cases, the infection closely resembles seborrheic dermatitis or dandruff of the scalp. A pathognomonic feature is hair loss; hair often breaks a few millimeters or more above the skin surface. Broken or infected hairs are also slightly swollen and have a dull appearance .

Trichoscopy is a non-invasive and very useful technique for the diagnosis and follow-up of hair and scalp disorders. The presence of certain trichoscopic features allows accurate identifying of tinea capitis. In tinea capitis, specific signs can be seen like comma hair, corkscrew hair, bar code-like hair and zigzag hair . In tinea incognito trichoscopic finding include erythema, scaling, bent hair, Morse code hair, and micropustules .

Mycological examination was first performed using Potassium Hydroxide(KOH) to confirm the diagnosis of tinea capitis where the patients with positive KOH were considered to have endothrix when observing arthroconidia inside the hair shaft and ectothrix when observing arthroconidia outside the hair shaft. The fungal culture also done to accurately recognize the organism through inoculation of samples on Sabouraud medium agar (SDA) with and without chloramphenicol(nonspecific medium) . And Dermasel medium agar act as specific medium.

The increase in antifungal resistance has recently been observed worldwide and resistant strains of the dermatophytes T. rubrum and T. indotineae have spread globally, causing outbreaks of extensive, difficult to treat infections , so we need rapid and reliable diagnostic tools that provide clues regarding the causative organisms.

02

Conditions studied

  • Fungal Infection by Site
  • Tinea Capitis

Keywords

  • Tinea capitis
  • antifungal resistance
  • dermatophyte
  • KOH
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted at the Dermatology Outpatient Clinic in Sohag University Hospitals.

Study population: The study population will be all patients with tinea capitis both male and female in childhood period, Aged 1-18 years old

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Both male and female in childhood period (1-18 years) with tinea capitis

Exclusion criteria

Exclusion Criteria:

  • Topical or systemic antifungal medications one month prior to enrollment in the study
  • Presence of systemic disease, such as hepatic,renal, cardiac, diseases, or
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • patients with tinea capitis both male and female in childhood period

    Diagnostic Test: Dermoscopic examination: the findings are divided into pathognomic and non-specific signs · Diagnostic Test: Direct Microscopy (KOH) examination · Diagnostic Test: Fungal culture: · Diagnostic Test: Antifungal sensitivity:

Interventions

  • Diagnostic testDermoscopic examination: the findings are divided into pathognomic and non-specific signs

    1. Pathognomic signs: comma hairs, corkscrew hairs, Morse code like hairs and zig-zag hairs. 2. Non-specific signs: black dots, broken hairs, perifollicular scaling and inter follicular erythema

  • Diagnostic testDirect Microscopy (KOH) examination

    1. Suspected lesions will be swabbed with 70% ethyl alcohol then scalp scraping using the blunt edge of a sterile surgical blade 2. Skin scales and crusts will be collected from the erythematous, peripheral, actively expanding edges of the lesions onto clean glass slides by scraping the inflamed lesions the scales will contain infected stumps of hair 3. Hair will be removed with the root intact (hair cutting will be avoided) 4. Specimen will be prepared by mounting the sample in (10-30%) of potassium hydroxide with 40% Dimethyle sulphoxide (DMSO) drops on the petri slide to soften the tissue, allowing a thin layer of cells to form.

  • Diagnostic testFungal culture:

    Specimen will be cultured on sabouraud's dextrose agar (SDA) at 25 -30 c for 2 to 4 weeks and another specimen will be cultured on a Dermasel agar base (Oxoid, UK), both supplemented with chloramphenicol and cycloheximide , staining the fungal colonies by Lactophenol cotton blue to help the examination of colonial morphology and microscopic examination of the macro-conidia allow the identification of the dermatophyte species and suitable treatment

  • Diagnostic testAntifungal sensitivity:

    Antifungal susceptibility testing will be performed to determine the specific sensitivity profiles of the fungal isolates. Antifungal susceptibility testing will be performed using seven antifungal agents: Terbinafine, Itraconazole, Griseofulvin, Fluconazole, Ketoconazole, Vorioconole and Miconazole. Dermatophytes colonies will be probed from Dermasel agar cultures.

06

What researchers measure

Primary outcomes

  1. Percentage of participants presenting with specific clinical patterns of tinea capitis

    Clinical evaluation will be performed to identify and classify the presentation of tinea capitis lesions (e.g., scaly patches, black dots, kerion, favus).

    Time frame: At the time of initial clinical evaluation

  2. Percentage of participants exhibiting specific dermoscopic features of tinea capitis

    Dermoscopic examination using a handheld dermatoscope to identify characteristic signs including comma hairs, corkscrew hairs, broken hairs, and scaling.

    Time frame: At the time of initial dermoscopic evaluation

  3. Prevalence of isolated fungal species among pediatric tinea capitis cases

    Mycological evaluation including direct microscopic KOH preparation and fungal culture on agar media to isolate and identify the causative fungal pathogens.

    Time frame: At the time of initial sample collection and culture identification

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07802600
Lead sponsor
Sohag University
Responsible party
Walaa Hemdan Aboelhasan (principal investigator ,demonstrator of dermatology and andrology, Sohag University) — Principal investigator
First posted
Sep 3, 2026
Start date
Sep 20, 2026 (estimated)
Primary completion
Nov 20, 2026 (estimated)
Completion
Aug 20, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Noha Shafik, Assistant professor
Contact
nohasaber@med.sohag.edu.eg
01067261504
Walaa Hemdan Abu Alhassan, Demonstrator
Contact
Mohammed Abu El Hamd Ali
study chair · Faculty of Medicine , Sohag university
Doaa Gaber Abdelbaset
study chair · Faculty of Medicine , Sohag university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion